Vascular growth factors and lymphangiogenesis

Physiological Reviews

Volumn 82, Issue 3, 2002, Pages 673-700

  Jussila, Lotta ^a   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; ANTIMETASTATIC AGENT; CELL MARKER; EPHRIN; NEUROPILIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; BLOOD VESSEL; CELL CULTURE; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; GENE THERAPY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; ISCHEMIA; KAPOSI SARCOMA; LYMPH FLOW; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHEDEMA; METASTASIS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; TUMOR VASCULARIZATION; VASCULAR TUMOR;

EID: 0036306121     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.00005.2002     Document Type: Review

References (232)

1. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature
2. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect
3. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flkl) and VEGF receptor 3 (Flt4)
4. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
5. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis
6. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues
7. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
8. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
9. Chemotherapy targeted to tumor vasculature
10. Isolation of putative progenitor endothelial cells for angiogenesis
11. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man
12. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymphspecific receptor for hyaluronan
13. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells
14. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1
15. Use of anti-basement membrane antibodies to distinguish blood vessel capillaries from lymphatic capillaries
16. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
17. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
18. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
19. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
20. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor
21. Vascular smooth muscle growth: Autocrine growth mechanisms
22. Developmental roles of platelet-derived growth factors
23. Platelet-derived growth factor: A key regulator of connective tissue cells in embryogenesis and pathogenesis
24. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer
25. Lymphatic microvessel density in epithelial ovarian cancer: Its impact on prognosis
26. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
27. P53 and angiogenesis
28. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
29. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium
30. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma
31. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
32. Arteriogenesis versus angiogenesis: Two mechanisms of vessel growth
33. Tsang ML-S Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR
34. Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing
35. Vascular endothelial growth factor C induces angiogenesis in vivo
36. Mechanisms of angiogenesis and arteriogenesis
37. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
38. Angiogenesis in cancer and other diseases
39. The emerging role of the bone marrowderived stem cells in (therapeutic) angiogenesis
40. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
41. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
42. LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and downregulation in human liver cancer and cirrhosis
43. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
44. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells
45. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration
46. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
47. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
48. Vascularization of the mouse embryo: A study of flk-1, tek, tie and VEGF expression during development
49. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
50. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
51. Tumors: Wounds that do not heal. Similarity between tumor stroma generation and wound healing
52. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
53. Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing
54. Anti-cancer activity of targeted pro-apoptotic peptides
55. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin
56. Comparison of VEGF, VEGF-B VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
57. Mapping of primary congenital lymphedema to the 5q35.3 region
58. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome
59. VEGF: An update on biological and therapeutic aspects
60. Role of vascular endothelial growth factor in regulation of physiological angiogenesis
61. Clinical applications of angiogenic growth factors and their inhibitors
62. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
63. The biology of vascular endothelial growth factor
64. Hereditary lymphedema: Evidence for linkage and genetic heterogeneity
65. Angiogenesis in cancer, vascular, rheumatoid and other disease
66. Angiogenesis and tumor growth
67. Blood vessel formation: What is its molecular basis?
68. Induction of angiogenesis during the transition from hyperplasia to neoplasia
69. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
70. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
71. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
72. Roles of a neuronal cell-surface molecule, neuropilin, in nerve fiber fasciculation and guidance
73. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
74. Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene
75. The enigmas of Kaposi's sarcoma
76. Vascular tumors and vascular malformations: Evidence for an association
77. Purification and characterization of a growth factor-like which increases capillary permeability from Vipera lebetina venom
78. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
79. VEGF is required for growth and survival in neonatal mice
80. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
81. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
82. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines
83. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
84. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis
85. Signaling vascular morphogenesis and maintenance
86. The hallmarks of cancer
87. Openings between defective endothelial cells explain tumor vessel leakiness
88. Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host anti-tumor defense mechanism
89. Mechanism of action and in vivc role of platelet-derived growth factor
90. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis
91. Role of PDGF-B and PDGFR-beta in recruitment of vascula-smooth muscle cells and pericytes during embryonic blood vesse formation in the mouse
92. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbi aorta
93. Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus
94. The anatomy and development of the jugular lymph sac in the domestic cat (Felis domestica)
95. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
96. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
97. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
98. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
99. Proteolytic processing regulates receptor specificity and activity of VEGF-C
100. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3
101. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: Role of VEGF-receptor 2 and host VEGF-A
102. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development
103. A model for gene therapy of human hereditary lymphedema
104. Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema
105. Lymphatic endothelium: A new frontier of metastasis research
106. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
107. Lymphatic vessels as targets of tumor therapy?
108. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth
109. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
110. A requirement for neuropilin-1 in embryonic vessel formation
111. Vascular permeability factor, an endothelial cell mitogen related to PDGF
112. Tumor angiogenesis: Past, present and the near future
113. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
114. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo
115. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas
116. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
117. Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper)
118. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages
119. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
120. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
121. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer
122. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1
123. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?
124. Identification of an angiogenic mitogen selective for endocrine gland endothelium
125. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation
126. Diseases of the veins and lymphatic vessels, including angiodysplasias
127. Vascular endothelial growth factor is a secreted angiogenic mitogen
128. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities
129. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor
130. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
131. Endogenous ligands of carbohydrate recognition domains of the mannose receptor in murine macrophages, endothelial cells and secretory cells: Potential relevance to inflammation and immunity
132. A combinatorial role of angiopoietin-1 and orphan receptor TIE1 pathways in establishing vascular polarity during angiogenesis
133. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
134. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
135. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14
136. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
137. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
138. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1
139. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3
140. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
141. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
142. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
143. Neuropilin-1 is a placenta growth factor-2 receptor
144. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo
145. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors
146. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma
147. A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
148. VEGF VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
149. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
150. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
151. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
152. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11
153. Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo
154. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing
155. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
156. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice
157. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
158. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
159. VEGF-C VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues
160. Endothelial growth factor receptors in human fetal heart
161. Lymphangiogenesis and tumor metastasis: Myth or reality?
162. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
163. Signaling via vascular endothelial growth factor receptors
164. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
165. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium
166. Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development
167. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells
168. Circulating endothelial precursors: Mystery, reality, and promise
169. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumour angiogenesis
170. Mechanisms of angiogenesis
171. Vasculogenesis
172. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C
173. Mouse mutants and cardiac development: New molecular insights into cardiogenesis
174. Expression of angiogenic factors and structural proteins in central nervous system vascular malformations
175. Targeting tumor vasculature with homing peptides from phage display
176. An address system in the vasculature of normal tissues and tumors
177. Lymphatics of the skin
178. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig
179. On the development of the superficial lymphatics in the skin of the pig
180. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
181. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
182. Complexus adhaerentes, a new group of desmoplakin-containing junctions in endothelial cells: The syndesmos connecting retothelial cells of lymph nodes
183. Lymphangioblasts in the avian wing bud
184. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
185. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice
186. Evidence for circulating bone marrow-derived endothelial cells
187. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
188. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells
189. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma
190. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma
191. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer
192. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain
193. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
194. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice
195. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
196. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers
197. Oncotic pressure in solid tumors is elevated
198. Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorigenesis
199. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
200. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2
201. Angiopoietin-1 protects the adult vasculature against plasma leakage
202. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
203. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
204. Evidence for a second valve system in lymphatics: Endothelial microvalves
205. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
206. Endothelial cell phenotypic diversity. In situ demonstration of immunologic and enzymatic heterogeneity that correlates with specific morphologic subtypes
207. Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes
208. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
209. Lymphangiogenesis and lymph node microdissemination
210. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
211. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2
212. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
213. Stimulation of β1 integrin induces tyrosine phosphorylation of VEGF receptor-3 and modulates cell migration
214. Angiogenesis in ischemic heart disease
215. Tumor angiogenesis: Review of current applications in tumor prognostication
216. Proxl function is required for the development of the murine lymphatic system
217. Embryonic angiogenesis: A review
218. Expression of the avian VEGF receptor homologues Quek1 and Quek2 in blood-vascular and lymphatic endothelial and non-endothelial cells during quail embryonic development
219. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1
220. Phenotypic and genotypic heterogeneity in familial Milroy lymphedema
221. Lymphangiogenesis: Mechanisms, significance and clinical implications
222. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
223. Gastrointestinal cancer metastasis and lymphogenous spread: Viewpoint of animal models of lymphatic obstruction
224. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border
225. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
226. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta